Ren Jing-Yi, Song Jun-Xian, Lu Ming-Yu, Chen Hong
Department of Cardiology, Peking University People's Hospital, Beijing 100044, China.
Regul Pept. 2011 Aug 8;169(1-3):49-57. doi: 10.1016/j.regpep.2011.04.004. Epub 2011 May 7.
We previously found that the expression of transient receptor potential vanilloid 1 (TRPV1) and contents of calcitonin gene-related peptide (CGRP) and substance P (SP), two main neuropeptides released from TRPV1, were decreased in diabetic hearts. This study aimed to test whether decreased TRPV1, CGRP and SP levels were responsible for the loss of cardioprotection by ischemic postconditioning (IPostC) in isolated perfused heart from streptozotocin-induced diabetic rats. IPostC effectively protected non-diabetic hearts against ischemia/reperfusion injury by improving cardiac function and lowering creatine kinase (CK) and cardiac troponin I (cTnI) release, which could be abolished by inhibiting TRPV1, CGRP receptor or SP receptor. However, IPostC had no effect on cardiac function and the release of CK and cTnI in diabetic hearts regardless of whether TRPV1, CGRP receptor or SP receptor were inhibited. CGRP or SP-induced postconditioning significantly prevented both non-diabetic and diabetic hearts from ischemia/reperfusion injury by improving cardiac function and lowering CK and cTnI release. Additionally, IPostC markedly increased CGRP and SP release in non-diabetic hearts, which could be reversed with TRPV1 inhibition, but not CGRP receptor or SP receptor inhibition. However, IPostC failed to affect CGRP and SP release in diabetic hearts in the presence or absence of TRPV1, CGRP receptor or SP receptor inhibition. These results indicate that the loss of cardioprotection by IPostC during diabetes is partly associated with a failure to increase CGRP and SP release, likely due to decreased TRPV1 expression and CGRP and SP contents in diabetic hearts.
我们之前发现,瞬时受体电位香草酸亚型1(TRPV1)的表达以及降钙素基因相关肽(CGRP)和P物质(SP)的含量在糖尿病心脏中降低,CGRP和SP是从TRPV1释放的两种主要神经肽。本研究旨在测试TRPV1、CGRP和SP水平降低是否是链脲佐菌素诱导的糖尿病大鼠离体灌注心脏中缺血后处理(IPostC)心脏保护作用丧失的原因。IPostC通过改善心脏功能并降低肌酸激酶(CK)和心肌肌钙蛋白I(cTnI)的释放,有效保护非糖尿病心脏免受缺血/再灌注损伤,而抑制TRPV1、CGRP受体或SP受体可消除这种保护作用。然而,无论是否抑制TRPV1、CGRP受体或SP受体,IPostC对糖尿病心脏的心脏功能以及CK和cTnI的释放均无影响。CGRP或SP诱导的后处理通过改善心脏功能并降低CK和cTnI的释放,显著预防了非糖尿病和糖尿病心脏的缺血/再灌注损伤。此外,IPostC显著增加了非糖尿病心脏中CGRP和SP的释放,抑制TRPV1可使其逆转,但抑制CGRP受体或SP受体则不能。然而,无论是否存在TRPV1、CGRP受体或SP受体抑制,IPostC均未能影响糖尿病心脏中CGRP和SP的释放。这些结果表明,糖尿病期间IPostC心脏保护作用的丧失部分与无法增加CGRP和SP的释放有关,这可能是由于糖尿病心脏中TRPV1表达以及CGRP和SP含量降低所致。